Reported about 12 hours ago
Large-cap biotechs are gaining attention from investors due to their potential growth and upcoming portfolios that may compete with traditional pharma companies. Unlike their larger pharmaceutical counterparts, which typically have broader and more diversified technologies, large-cap biotechs focus on specialized areas, often driven by single-technology pipelines. As major pharmaceutical firms increasingly look to invest in these biotech companies, experts believe that some of them could soon stand alongside traditionally established big pharma players, reshaping the industry's landscape.
Source: YAHOO